Celyad Oncology
(NASDAQ) CYAD
This security has been delisted. This page is retained for historical reference.
CYAD News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCYAD Financials
Key Financial Metrics (TTM)
Gross Margin
9195.24%
Operating Margin
-33957.14%
Net Income Margin
3833.33%
Return on Equity
-242.11%
Return on Capital
-79.57%
Return on Assets
18.73%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
-€190.00K
Operating Income
-€16.39M
EBITDA
-€14.51M
Operating Cash Flow
-€29.74M
Capital Expenditure
-€950.00K
Free Cash Flow
-€30.69M
Cash & ST Invst.
€6.23M
Total Debt
€989.00K
Celyad Oncology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
€172.00K
N/A
Gross Profit
€169.00K
+136.0%
Gross Margin
98.26%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
35
N/A
Net Income
-€2.78M
+89.7%
EBITDA
-€2.83M
+89.3%
Quarterly Fundamentals
Total Cash
€6.23M
-56.7%
Total Debt
€989.00K
-54.3%
Accounts Receivable
€74.00K
-98.0%
Inventory
€0.00
N/A
Long Term Debt
€834.00K
-39.6%
Short Term Debt
€155.00K
-80.2%
Return on Assets
18.73%
N/A
Return on Invested Capital
-2.88%
N/A
Free Cash Flow
-€2.83M
+82.8%
Operating Cash Flow
-€2.83M
+82.6%